Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on March 1, 2021
February 25 2021 - 8:37AM
Business Wire
Omeros Corporation (NASDAQ: OMER), today announced that the
company will issue its fourth quarter and year-end financial
results for the period ended December 31, 2020, on Monday, March 1,
2021, after the market closes. Omeros management will host a
conference call and webcast that day at 4:30 p.m. Eastern Time
(1:30 p.m. Pacific Time) to discuss the financial results as well
as recent developments and highlights.
Conference Call Details
To access the live conference call via phone, please dial (844)
831-4029 from the United States and Canada or (920) 663-6278
internationally. The participant passcode is 3399452. Please dial
in approximately 10 minutes prior to the start of the call. A
telephone replay will be available for one week following the call
and may be accessed by dialing (855) 859-2056 from the United
States and Canada or (404) 537-3406 internationally. The replay
passcode is 3399452.
To access the live and subsequently archived webcast of the
conference call, go to Omeros’ website at www.omeros.com and select
“Events” under the Investors section of the website. Please connect
to the website at least 15 minutes prior to the call to allow for
any software download that may be necessary.
About Omeros Corporation
Omeros is a commercial-stage biopharmaceutical company committed
to discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting inflammation, complement-mediated diseases, disorders of
the central nervous system and immune-related diseases, including
cancers. Its commercial product OMIDRIA (phenylephrine and
ketorolac intraocular solution) 1%/0.3% continues to gain market
share in cataract surgery. Omeros’ lead MASP-2 inhibitor
narsoplimab targets the lectin pathway of complement and is the
subject of a rolling biologics license application under priority
review by FDA for the treatment of hematopoietic stem cell
transplant-associated thrombotic microangiopathy. Narsoplimab is
also in multiple late-stage clinical development programs focused
on other complement-mediated disorders, including IgA nephropathy,
atypical hemolytic uremic syndrome and COVID-19. Omeros’ MASP-3
inhibitor OMS906, which targets the complement system’s alternative
pathway, recently entered the clinic, and the company’s PDE7
inhibitor OMS527 has successfully completed its Phase 1 trial.
Omeros’ pipeline holds a diverse group of preclinical programs
including a novel antibody-generating technology and a proprietary
GPCR platform through which it controls 54 new GPCR drug targets
and their corresponding compounds. One of these novel targets,
GPR174, modulates a new cancer immunity axis recently discovered by
Omeros, and the company is advancing small-molecule GPR174
inhibitors. For more information about Omeros and its programs,
visit www.omeros.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210225005726/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations 360.668.3701
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2023 to Apr 2024